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Abstract 
Background: Cost effectiveness was a criterion used to revise Ethiopia’s essential health service package (EHSP) in 
2019. However, there are few cost-effectiveness studies from Ethiopia or directly transferable evidence from other 
low-income countries to inform a comprehensive revision of the Ethiopian EHSP. Therefore, this paper reports average 
cost-effectiveness ratios (ACERs) of 159 health interventions used in the revision of Ethiopia’s EHSP.
Methods: In this study, we estimate ACERs for 77 interventions on reproductive maternal neonatal and child health 
(RMNCH), infectious diseases and water sanitation and hygiene as well as for 82 interventions on non-communicable 
diseases. We used the standardised World Health Organization (WHO) CHOosing Interventions that are cost effective 
methodology (CHOICE) for generalised cost-effectiveness analysis. The health benefits of interventions were deter-
mined using a population state-transition model, which simulates the Ethiopian population, accounting for births, 
deaths and disease epidemiology. Healthy life years (HLYs) gained was employed as a measure of health benefits. We 
estimated the economic costs of interventions from the health system perspective, including programme overhead 
and training costs. We used the Spectrum generalised cost-effectiveness analysis tool for data analysis. We did not 
explicitly apply cost-effectiveness thresholds, but we used US$100 and $1000 as references to summarise and present 
the ACER results.
Results: We found ACERs ranging from less than US$1 per HLY gained (for family planning) to about US$48,000 per 
HLY gained (for treatment of stage 4 colorectal cancer). In general, 75% of the interventions evaluated had ACERs of 
less than US$1000 per HLY gained. The vast majority (95%) of RMNCH and infectious disease interventions had an 
ACER of less than US$1000 per HLY while almost half (44%) of non-communicable disease interventions had an ACER 
greater than US$1000 per HLY.
Conclusion: The present study shows that several potential cost-effective interventions are available that could 
substantially reduce Ethiopia’s disease burden if scaled up. The use of the World Health Organization’s generalised 
cost-effectiveness analysis tool allowed us to rapidly calculate country-specific cost-effectiveness analysis values for 
159 health interventions under consideration for Ethiopia’s EHSP.
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Background
Priority setting allows consensus to be reached on 
which interventions to include in an essential health 
service package (EHSP), on which interventions to 
scale up first and on which intervention to scale 
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down [1–3]. In this process, various approaches can 
be applied to compare interventions, of which cost 
effectiveness is the most widely used globally [4]. 
Cost-effectiveness analysis (CEA) plays a central role 
in decision making in many health technology assess-
ment agencies in high-income countries [5], and there 
has recently been a growing interest in using cost 
effectiveness in defining national EHSPs in low- and 
middle-income countries [6].
In the Ethiopian EHSP revision, cost effectiveness 
was a criterion chosen to compare health interven-
tions in terms of value for money [7], but there are 
only a few CEAs of health interventions from Ethiopia 
and other low-income countries. For instance, Hailu 
et al. examine the cost effectiveness of malaria preven-
tion interventions [8], Memirie et  al. examine that of 
maternal and neonatal interventions [9], Strand et  al. 
evaluate that of neuropsychiatric services [10], and 
Tolla et al. examine that of cardiovascular disease pre-
vention and treatment interventions [11].
Most of those studies applied an incremental cost-
effectiveness approach that compares the cost effec-
tiveness of adding new interventions against the 
current practice in the area [12]. This approach 
assumes that the current practice is organised in the 
most efficient way possible and thus does not account 
for existing inefficiencies in the health system. With 
incremental/marginal analysis, it is difficult to exam-
ine whether the current mix of interventions repre-
sents an efficient use of resources [12, 13]. Although 
these pieces of evidence are vital in informing the set-
ting of priorities in decision making in specific sub-
programme areas or for specific diseases, particularly 
when the existing package is assumed to allocate effi-
ciently, they are less relevant in informing the sector-
wide analysis of EHSP revisions [14, 15].
Therefore, the World Health Organization (WHO), 
in its CHOosing Interventions that are Cost Effec-
tive (CHOICE) programme, proposes a generalised 
CEA that compares all interventions with ‘doing noth-
ing’ or a ‘null scenario’ [13]. This approach assesses 
whether the current mix of interventions is efficient 
and whether a proposed new technology or interven-
tion is appropriate. It also provides decision makers 
with information on what they could achieve if they 
reallocated resources in the most efficient way. This 
approach provides broader generalisability of the CEA 
results and is considered an appropriate method for 
redefining an EHSP [13]. Therefore, this paper uses 
the WHO-CHOICE tool to calculate an ACER for the 
159 relevant health interventions for use in the revi-
sion of Ethiopia’s EHSP.
Methods
Study population and context
This study was conducted in Ethiopia in 2019 as part of 
the revision of the country’s EHSP [7]. Ethiopia has a 
large disease burden, with average life expectancy of 65.5 
[16, 17]. Communicable, maternal, neonatal, and nutri-
tional disorders (CMNNDs) represent the greatest dis-
ease burden, accounting for 58% of disability-adjusted life 
year (DALY) loss in 2017. In the same year, the burden 
of NCDs, such as cardiovascular diseases, diabetes and 
cancer, accounted for 34% of the burden. About 8% of 
the DALYs were from emergencies and injuries [17]. Fur-
thermore, Ethiopia is a low-income country, with a Gross 
Domestic Product (GDP) per capita of US$953 in 2019 
[18] and a per capita health expenditure of about US$33 
in 2016/17 [19]. Further reduction or slow increment of 
the health expenditure is expected in Ethiopia because 
of the impact of COVID-19 pandemic on the economic 
growth of the country and its global impact. Therefore, it 
is crucial to invest limited resources efficiently.
Interventions
A breakdown of interventions by the conditions they pre-
vent or treat is provided in Table 1. A total of 1018 inter-
ventions were analysed for the EHSP. The current version 
of the WHO-CHOICE generalised cost-effectiveness 
analysis (GCEA) tool includes about 400 interventions 
[20], of which 159 were found to be relevant for the Ethi-
opian EHSP. We grouped the 159 interventions into 12 
groups that matches with the sub-programme areas clas-
sification of intervention list in the EHSP. In general, and 
slightly over half of them fell under either reproductive, 
maternal, neonatal and child health (RMNCH) (28.3%), 
mental health (12.6%) or policies against NCDs (10.1%), 
such as physical inactivity, excessive alcohol use and 
tobacco, sugar and salt intake (Table 1).
Health effects of the interventions
We used the WHO-CHOICE GCEA tool to analyse the 
country-level health benefits of each intervention [21]. 
This model examines for each disease of interest (by inci-
dence, remission and case fatality rates) how proportions 
of the population transit between health states in the 
presence or absence of an intervention. The Global Bur-
den of Disease disability weights were used to evaluate 
the health state in the time spent in each health state, and 
the health effects generated by each intervention are pre-
sented as healthy life years (HLYs) gained [22].
We applied various integrated impact-modelling 
modules of the latest version of Spectrum software 
to model the health benefits of each intervention [22] 
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and applied the DemProj module to project population 
growth and other underlying demographic parameters 
(Table  1). This module uses World Population Pros-
pects 2017 data from the United Nations Population 
Division. The FamPlan module was used to estimate the 
impact of family planning interventions. In this module, 
we used data from the 2016 Ethiopian Demographic 
Health Survey. We employed the AIDS Impact Mod-
ule (AIM) (which was initially developed by UNAIDS 
to make national and regional HIV estimates every 
2 years) to estimate the impact of interventions against 
HIV, and we employed the TIME Estimates and TIME 
impact Module to estimate the health impact of tuber-
culosis (TB) interventions. For RMNCH, nutrition and 
Water sanitation and hygiene (WASH) interventions, 
the Lives Saved Tool (LiST) module was employed, and 
we used the non-communicable disease impact mod-
ule to calculate the impact of NCD policy interventions 
and other interventions against cancer and respiratory 
disease as well as mental health, neurological and sub-
stance use disorders [22].
The spectrum software includes default input for 
many countries based on data from various sources 
(i.e. systematic reviews, individual studies, national 
and regional reports, GBD etc.). We downloaded and 
used country-specific data for Ethiopia in the Spectrum 
software. The Country Data Package was prepopu-
lated with the total population, population in need, 
target population, disease burden and effect size for 
each intervention. We carefully reviewed all the default 
input with programme area experts at the Ministry 
of Health, and appropriate changes were made when 
deemed necessary. A more detailed explanation of each 
of the intervention input assumptions is provided else-
where [22, 23].
Costs of interventions
The identification, measurement and valuation of the 
costs of all the interventions were conducted from the 
health system’s perspective, accounting for the full cost 
of delivering an intervention, regardless of who cur-
rently pays for it. The ingredients costing approach was 
used, in which each input of delivering the intervention 
is identified and the quantity of each resource required 
by the intervention is multiplied by the unit price of 
each input (i.e., the unit price × quantity approach 
was applied) [12]. In the WHO-CHOICE GCEA tool, 
all the ingredients, based on expert recommendations, 
are provided as default values, and the country team 
reviewed the inputs and made changes when neces-
sary. For example, all the drugs and supplies needed 
to provide each service were systematically identified, 
accounting for the cost of delivering the drugs and sup-
plies from the point of production or purchase to the 
point of use (i.e., the cost of transportation, storage, 
shipment and customs clearance). Default prices for 
drugs and suppliers within the GCEA tool are taken 
from an international drug price database (MSH). We 
updated the prices of some drugs and supplies based 
on data from the Ethiopian Pharmaceutical Supply 
Agency and the Logistics Department of the Ministry 
of Health. To account for the cost of delivering drugs 
and supplies, an average mark-up of 6% of the price was 
generally taken. For drugs needing a cold supply chain, 
Table 1 Frequency and proportion of interventions evaluated by sub-programme area, 2019
The level of detail varies across the sub-programme areas
Intervention by sub-programme area N % Spectrum impact model used
RMNCH 44 28.3 LiST, FamPlan
Mental health 20 12.6 NCD impact
Policy interventions on NCDs 16 10.1 NCD impact
Cervical cancer 13 8.2 NCD impact
Respiratory disease 12 7.6 NCD impact
Colorectal cancer 11 6.9 NCD impact
Breast cancer 10 6.3 NCD impact
Tuberculosis 10 6.3 TIME Estimates and TIME impact
Nutrition 9 5.7 LiST
HIV/AIDS 5 3.1 AIM and GOALS
Malaria 5 2.5 LiST
Water hygiene and sanitation 4 2.5 LiST
Total 159 100
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an additional 13% of the cost of the drug was taken as 
mark-up as the cold-chain system incurs an additional 
cost. For Long-lasting Insecticidal Nets (LLINs), a 26% 
mark-up was taken as LLINs are relatively bulky and 
their transportation, loading and unloading incur an 
additional cost [24].
Health personnel costs for providing the interventions 
were also included. The salary scale of the health work-
force, such as the salaries and benefits of nurses, doctors 
and pharmacists, was based on the most up-to-date data 
from the Human Resource Department of the Ministry 
of Health of Ethiopia. Staff time use was calculated on 
the assumption that, on average, each person works 8 h 
per day over 230 working days per year. Inpatient cost 
per day and outpatient cost per visit were taken from the 
WHO-CHOICE model [25].
Programme costs were also included in this analysis 
[24]. Programme costs are the non-health care delivery 
costs associated with delivering an intervention pro-
gramme that are incurred at a level other than the inter-
vention’s point of delivery. They include costs incurred 
at district, provincial or central levels and exclude costs 
incurred at facility or patient levels. They include the cost 
of administration and planning, media and communica-
tion, law enforcement, training, monitoring and evalua-
tion. All costs were valued using 2019 US dollars (USDs). 
All cost input data originally collected in Ethiopian Birr 
(ETB) were first converted to USD using the average 
exchange rate for the year and were later converted to 
2019 USD using the GDP deflator.
Cost-effectiveness analysis
To account for the impact of an intervention in the long 
term (steady state), we followed in this cost-effective-
ness analysis model a hypothetical Ethiopian population 
cohort over a 100-year time horizon starting in 2019. 
The average cost effectiveness of the intervention was 
computed as a ratio of the total cost of the intervention 
to total health life years (HLYs) gained from the inter-
vention [12, 26]. The interventions were ranked and 
compared based on their ACERs. Both costs and health 
outcomes were discounted at an annual rate of 3% [13].
Cost-effectiveness thresholds
A cost-effectiveness threshold (CET) is an explicit cut-
off point for assessing the opportunity cost of interven-
tions, with interventions having a cost-effectiveness ratio 
below the threshold being considered to offer good value 
for money [27]. There is a long-standing debate concern-
ing the CET [18, 28, 29]. In the case of sector-wide analy-
sis of health interventions using a GCEA, a CET is not 
required because the purpose of a GCEA is to compare 
the whole list of interventions against the comparator of 
doing nothing, and the ACERs of interventions should 
be compared with one another, even across programme 
areas, and not against a predefined CET [14, 15]. In this 
study, therefore, we did not apply a CET; instead, we 
report the ACERs in ascending order in bar graphs for 
each programme area. However, we use US$100 and 
US$1000 per HLY gained as references to summarise and 
present the ACER results.
Table 2 Summary of ACERs (USD per HLY) of the interventions by sub-programme areas
SD: standard deviation; p25: 25th percentile; p75: 75th percentile; Min: minimum; Max: Maximum; % < $1000: proportions of interventions within that program area 
with ACERs lower than $1000 per HLY
Sub-programme Mean SD Median p25 p75 Min Max % < $1000
HIV/AIDS 106 167 34 20 61 13 403 100
RMNCH 116 258 37 13 113 0.4 1591 97
WASH 122 219 16 9 234 5 451 100
Tuberculosis 143 12 139 137 147 129 163 100
Nutrition 262 312 72 37 580 31 746 100
Cervical cancer 870 1818 111 36 628 34 6534 77
Mental health 1045 1944 185 120 944 31 7610 75
Malaria 1163 1186 1310 79 1469 40 2915 40
NCD policy interventions 1834 2759 437 202 3053 26 9115 69
Breast cancer 2157 1895 1535 1032 2203 366 6104 20
Chronic respiratory diseases 2307 3344 809 368 1484 164 8856 50
Colorectal cancer 3920 1967 4646 2493 5436 783 5602 18
Overall 1014 1926 151 40 783 0.4 9115 75
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Results
In this study, we identified cost-effectiveness estimates 
for 159 interventions. An overview of the distribution of 
the ACERs is presented in Table 2. Of the total number 
of interventions evaluated in this study, 58 (37%) have an 
ACER of less than US$100 per HLY, 104 (65%) have an 
ACER of less than US$500 per HLY and 119 (75%) have 
an ACER of less than US$1000 per HLY gained.
Five interventions (basic palliative care for colo-
rectal cancer, colorectal cancer treatment at stage 4, 
relapse prevention medication for alcohol use/depend-
ence, inhaled short-acting beta-agonist for intermittent 
asthma and theophylline + high-dose inhaled beclometa-
sone + short-acting beta-agonist for asthma) have an 
ACER above US$10,000 per HLY. Therefore, in the sum-
mary statistics provided in Table 2, we exclude these five 
interventions as they represent extreme values.
We estimated ACERs ranging from less than US$1 per 
HLY gained (for family planning) to about US$48,000 per 
HLY gained (for treatment of stage 4 colorectal cancer). 
A large majority (97%) of RMNCH and infectious dis-
ease interventions had an ACER of less than US$1000 per 
HLY, and a substantial proportion (44%) of NCD inter-
ventions had an ACER of greater than US$1000 per HLY 
(Table 2).
We present the full costs and effectiveness of all the 
interventions in supplement table (Additional file  1). 
Below, we present the key findings for major programme 
areas.
Cost effectiveness of RMNCH interventions
All RMNCH interventions except zinc supplementation 
(ACER = 1591 USD/HLY) and ectopic pregnancy case 
management (ACER = 685 USD/HLY) had an ACER of 
less than US$400 per HLY (Fig. 1). The three most cost-
effective interventions in this category are prevent-
ing and managing unplanned pregnancy (ACER = 0.41 
USD/HLY), provision of family planning services alone 
Fig. 1 ACERs for RMNCH (Trimmed at US$350)
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(ACER = 0.42 USD/HLY) and provision of skilled assis-
tance for normal delivery, including postpartum family 
planning (ACER = 0.47 USD/HLY). All immunisation 
interventions cost less than US$100 (e.g., the Hib vac-
cine costs 49 USD/HLY, routine EPI + additional vac-
cines cost 68 USD/HLY and pneumococcal vaccine 
costs 86 USD/HLY).
Cost effectiveness of HIV/AIDS, TB and malaria 
interventions
All the HIV/AIDS interventions had an ACER of less 
than US$100 per HLY gained except cotrimoxazole 
for children, which costs US$403 per HLY. Paediatric 
anti-retroviral therapy (ART) costs US$20 per HLY, 
Prevention of Mother to Child Transmission (PMTC) 
of HIV costs US$61 per HLY, ART for adult women 
costs US$13 per HLY and ART for adult men costs 
US$34 per HLY. In this study, we evaluated four anti-
malaria interventions. While the use of insecticide-
treated materials costs US$79 per HLY and indoor 
residual spraying costs US$40 per HLY, Intermittent 
Preventive Therapy (IPT) for pregnant women costs 
US$1310 per HLY and treatment of malaria for preg-
nant women costs US$1469 per HLY. The 10 TB inter-
ventions evaluated in this study have ACERs ranging 
from US$129 per HLY (for the detection and treatment 
of multidrug-resistance tuberculosis (MDR-TB) using a 
smear or culture) to US$163 per HLY (for the detection 
and treatment of TB using a combination of smear and 
Xpert) (Fig. 2).
Of the 13 WASH and nutrition interventions in this 
study, the three most cost-effective were use of a water 
connection in the home (ACER = US$5 per HLY), 
handwashing with soap (ACER = US$13 per HLY) and 
improved excreta disposal (latrine/toilet) (ACER = US$13 
per HLY). Intermittent iron-folic acid supplementa-
tion for menstruating women where anaemia is a public 
health problem costs US$746 per HLY (Fig. 3).
Fig. 2 ACERs for HIV, TB and malaria interventions (Trimmed at US$500)
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Cost effectiveness of NCD policy interventions
For the 16 policy interventions against NCDs evaluated 
in this study, the ACERs range from a high of US$9115 
per HLY gained (for prevention of hazardous alcohol use 
using legal enforcement to restrict alcohol advertising) 
to a low of US$26 per HLY gained (for reduction of salt 
intake by harnessing/involving industries for reformula-
tion). Most of the tobacco prevention interventions were 
very cost effective. For instance, the ACER for protect-
ing people from tobacco smoke was US$232 per HLY 
while warning about the danger of tobacco using labels 
costs US$411 per HLY. The ACER for warning people 
about the danger of tobacco through mass media cam-
paigns was US$515 per HLY gained, for enforcing bans 
on tobacco advertising US$105 per HLY gained and for 
enforcing youth access restrictions on tobacco US$1728 
per HLY gained.
Intervention to enforce restrictions on the availability 
of retailed alcohol was US$4377 per HLY gained while 
screening and brief intervention for hazardous and 
harmful alcohol use was only US$579 per HLY gained. 
Most of the salt intake restriction interventions have the 
lowest cost-effectiveness ratios for Ethiopia. For instance, 
adopting standards in front-of-pack labelling costs US$42 
per HLY. Providing education and communication costs 
US$333 per HLY, and pursuing salt reduction strategies 
in community-based eating spaces costs US$173 per HLY 
gained (Fig. 4).
Cost effectiveness of cancer interventions
All the early detection and screening interventions for 
cervical cancer cost less than US$100 per HLY. For exam-
ple, a Papanicolaou test (Pap smear) costs US$34, visual 
inspection with acetic acid (VIA) costs US$35 and the 
HPV-DNA test costs US$60 per HLY gained. However, 
screening of breast cancer with clinical examination costs 
US$2203 per HLY and with mammography US$6104 per 
HLY. Similarly, colorectal cancer screening with sigmoi-
doscopy costs US$2493 and with colonoscopy US$5418 
per HLY (Fig. 5).
Cost effectiveness of mental health interventions
In this study, we examined 20 mental health interven-
tions. The provision of basic psychosocial treatment for 
mild depression is the most cost-effective intervention, 
with an ACER of US$31 per HLY, and basic psychosocial 
support for mild cases of anxiety disorder is the second 
most cost-effective (ACER = 67 USD/HLY). In the mental 
Fig. 3 ACERs for nutrition and WASH interventions
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health intervention category, relapse prevention medica-
tion for alcohol use/dependence is the least cost-effective 
intervention, costing US$37,616 per HLY (Fig. 6).
Cost effectiveness of chronic respiratory disease 
interventions
We examined 12 interventions under the chronic res-
piratory disease category, and the provision of smoking 
cessation interventions to prevent chronic obstructive 
pulmonary disease (COPD) is the most cost effective 
(ACER = 164 USD/HLY). The provision of an inhaled, 
short-acting beta-agonist for intermittent asthma is the 
least cost-effective in this category, with an ACER of 
US$15,440 per HLY (Fig. 7).
Discussion
This analysis aimed to provide input for the revision 
of Ethiopia’s EHSP, which used seven predefined and 
pre-agreed criteria, one being the cost effectiveness of 
interventions [7]. Our analysis encompasses a compre-
hensive range of health interventions, including preven-
tive, promotive, curative and policy interventions. Of 
the interventions analysed in this study, a large majority 
(75%) have ACERs of less than US$1000, and 36% have 
ACERs below US$100.
Cost-effectiveness analysis is an increasingly impor-
tant prioritisation tool. The cost-effectiveness evidence 
for redefining Ethiopia’s EHSP was generated in three 
ways: by contextualising CEA evidence from other stud-
ies using transferability criteria, by using expert opinion 
for multisectoral interventions and by using the WHO 
GCEA tool [7]. Using this tool, we provide cost-effec-
tiveness evidence for 159 relevant health interventions 
for EHSP revision in Ethiopia. We believe that other 
low-income countries in Africa can also generate these 
pieces of evidence within a relatively short time and at an 
affordable cost compared with individual economic eval-
uation studies.
We provide cost-effectiveness evidence for 77 inter-
ventions on RMNCH and infectious disease (e.g., HIV, 
TB, nutrition, malaria and WASH) and for 82 interven-
tions on NCDs. In general, a majority of the interven-
tions have relatively low ACERs of less than US$1000 per 
HLY gained. However, when we disaggregate the finding 
Fig. 4 ACERs for NCD policy interventions
Page 9 of 13Eregata et al. Cost Eff Resour Alloc            (2021) 19:2  
by programme area, the results are mixed. While a vast 
majority (95%) of RMNCH and infectious disease inter-
ventions have an ACER of less than US$1000 per HLY, a 
substantial proportion (44%) of NCD interventions have 
an ACER of higher than US$1000 per HLY. In general, 
findings from our study are consistent with findings of 
other country specific studies in Ethiopia, Zimbabwe, 
Mexico [8–10, 30–32], or other regional and global esti-
mates [33–38]. However, head to head comparison of the 
ACERs and further examination of cost, effectiveness, 
and its driving factors remain a priority for additional 
research.
Family planning interventions, for example, are the 
most cost effective in this study, with ACERs of less 
than US$1 per HLY gained. This very low ACER may be 
partly explained by the fact that the model accounts for 
a reduction in unplanned pregnancies and an associated 
reduction in maternal mortality. Most of the interven-
tions targeting infectious diseases were cost effective, 
with an ACER of less than US$500 per HLY. For example, 
we evaluated four HIV/AIDS interventions, and they all, 
except the provision of cotrimoxazole for children, have 
an ACER of less than US$100 per HLY gained. The rela-
tively low ACER in this study may partly reflect the dec-
rement of the price of ART drugs as is shown in several 
recent studies [39, 40].
Addressing maternal, neonatal and child health issues 
is a top priority of the Ethiopian Ministry of Health 
(MoH) [7]. In our study, the majority of the interven-
tions on RMNCH were very cost effective, with an 
ACER value of less than US$200 per HLY gained. This 
finding is in line with that of Memirie et  al. in a CEA 
examining the cost effectiveness of 13 maternal and neo-
natal health (MNH) interventions in Ethiopia. Although 
not a GCEA and therefore not directly comparable, that 
study found that 12 of 13 MNH interventions had an 
Fig. 5 ACERs for cancer interventions (Trimmed at US$10,000)
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incremental cost-effectiveness ratio of less than US$400 
per HLY [9].
Most of the preventive NCD policy interventions have 
a lower cost-effectiveness ratio than the treatment NCD 
interventions. A substantial proportion (44%) of NCD 
interventions have an ACER of greater than US$1000 per 
HLY. This relatively high ACER may reflect the fact that 
the treatment cost for chronic NCD is higher and the 
Fig. 6 ACERs for mental health interventions (Trimmed at US$10,000)
Fig. 7 ACERs for chronic respiratory disease interventions (Trimmed at US$10,000)
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treatment effectiveness lower than for the other interven-
tions. This is particularly consistent with findings from a 
comprehensive, but relatively old study, examining 101 
NCD interventions in Mexico. The study find similar var-
iations among NCD policy interventions and NCD treat-
ment interventions as we do [30].
Strengths and limitations
By applying the GCEA approach, it is possible to evalu-
ate whether the current mix of interventions is efficient 
and whether proposed new interventions are appropri-
ate. Therefore, GCEA is a more appropriate approach 
than a marginal analysis for conducting a sector-wide 
cost-effectiveness analysis of interventions [14, 15]. In 
this study, which included 159 interventions from diverse 
programme areas, we conducted a sector-wide cost-effec-
tiveness analysis. Although this study covers a substan-
tial number of crucial interventions, it did not attempt 
to analyse all interventions in the Ethiopian health sec-
tor. We believe, however, that our findings can be used 
as benchmarks for making better-informed expert judge-
ments on other interventions that could not be analysed 
in such a standardised way.
WHO-CHOICE GCEA tool is important tool for sec-
tor-wide analysis of cost-effectiveness of wider range of 
interventions for priority setting. A primary advantage of 
the WHO-CHOICE GCEA tool is the ability to compare 
many interventions at the same time based on the same 
assumptions on cost, disease epidemiology and other key 
health system parameters (e.g., human resource, financ-
ing, and infrastructure). When health system plans and 
strategies are designed, we should evaluate and compare 
the costs and outcomes of combinations of interven-
tions. However, a barrier to conducting economic evalua-
tion studies is that they are time consuming and demand 
large amounts of local data and local technical expertise. 
We believe that this study demonstrates that the existing 
platform, with a large support team and substantial com-
mitment, makes such an extensive and comprehensive 
evaluation possible.
Our work has other limitations. First, in this study, we 
used the health system perspective. In Ethiopia, one-
third of the total health care cost is covered by the out-
of-pocket expenditure of individuals [19], which can 
influence individuals’ choices in accessing health care 
delivery. The choice of perspective should also be taken 
into consideration when interpreting the results. Second, 
in this GCEA study, we applied data from diverse sources 
to model the health impact of interventions and costs. Of 
course, modelling is inevitably an imperfect representa-
tion of reality, and, therefore, robust uncertainty analysis 
would to some extent alleviate this challenge. However, 
because of the vast number of interventions included 
in this analysis, we did not include a sensitivity analysis. 
Therefore, as the software expands, future GCEA analy-
sis of this kind should integrate a sensitivity analysis of 
at least some of the critical drivers of costs and health 
impacts.
A third limitation of this study is the use of DALYs 
for estimating disease burden and health benefit. Crit-
ics of DALY argue that the measure itself has limita-
tions [41, 42]. Using DALYs tends to underrepresent 
or overestimate the value of interventions (such as pal-
liative care and family planning) with outcomes that are 
not readily measured in this metric as well as interven-
tions in nutrition for which the outcomes are improved 
cognition rather than improved health [43]. This is a real 
limitation that was taken seriously in the revision of Ethi-
opia’s EHSP. For these interventions, we also relied on 
the expanded EHSP process with user involvement and 
expert judgements. Furthermore, criteria other than cost 
effectiveness, such as equity, financial risk protection, 
budget impact and public concern are also important for 
defining the EHSP [3]. A fourth limitation of this study 
is that the models used do not capture full health ben-
efits. The most striking example is the LiST model which 
mainly considers mortality outcomes. Future analysis 
should also account for health benefits from RMNCH 
interventions that avert non-fatal conditions.
Additionally, there are gaps in the available evidence 
on the cost of interventions, which can be closed only 
by conducting substantially more research in developing 
countries. Therefore, we recommend a concerted effort 
to establish country-level cost databases. This could be 
combined with capacity building through the training of 
researchers to generate such evidence.
Conclusion
Through the process described above, we calculated 
country-specific CEA values which were required to 
inform the decisions around which interventions to pro-
vide under Ethiopia’s essential health service package 
(EHSP). The present study shows that several potential 
cost-effective interventions are available in all program 
areas that could substantially reduce Ethiopia’s disease 
burden if scaled up.
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